TEM stock forecast, quote, news & analysis
Tempus AI Inc is a technology company... Show more
Tempus AI (TEM) Stock Analysis: Oncology AI Partnerships Ignite Momentum
Key Takeaways
- Tempus AI's shares have gained traction in recent weeks, driven by advancements in cancer diagnostics and strategic collaborations.
- New oncology test kit launch triggered a significant single-day surge, highlighting product innovation potential.
- Analyst consensus leans toward buy ratings, with an average price target exceeding current levels amid 2026 revenue growth outlook.
- Robust data and applications segment fuels revenue expansion in precision medicine.
- Investors should monitor execution on partnerships and path to profitability in competitive AI healthcare landscape.
Current Market Snapshot
Tempus AI (TEM) has demonstrated resilience and upward momentum in recent trading sessions, navigating volatility within its established 52-week range. The stock reflects growing investor interest in its AI-powered precision medicine platform, particularly in oncology applications. Recent price action underscores positive sentiment tied to product innovations and partnerships, with market capitalization expanding notably over the past month. Trading volumes remain elevated, signaling sustained attention from institutional players. While macroeconomic pressures in healthcare tech persist, TEM's focus on data-driven diagnostics positions it favorably amid sector tailwinds.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from a library of over 350 bots that analyze and trade thousands of tickers across stocks, ETFs, and cryptocurrencies. These bots employ diverse strategies—from swing trading on industrial dips to scalping semiconductors in 5-minute timeframes—tailored to current market conditions like volatility in tech and energy sectors. Featured bots display impressive stats, including annualized returns ranging from 26% to over 120%, win rates of 55% to 87%, and profit factors up to 11.7, with average trade durations from hours to weeks. For instance, semiconductor-focused bots on tickers like NVDA and SOXL boast 65-97% annualized gains, while multi-agent systems cover gold miners and finance stocks. This dynamic leaderboard highlights bots best suited for today's environment, offering users real-time signals with built-in risk management for copy trading. Explore the Trending AI Robots to identify strategies aligning with TEM or broader portfolios.
Recent Developments Driving TEM Price Action
Tempus AI (TEM) has experienced notable price appreciation in the past 30 days, climbing from the low $40s to around $57, a gain fueled by a series of oncology-focused advancements and collaborations that bolstered investor confidence in its AI-driven precision medicine capabilities.
A key catalyst was the unveiling of a new cancer test kit, which propelled shares up 13.9% in a single session. This innovation underscores Tempus AI's push into diagnostics, leveraging its vast multimodal data library to enhance clinical decision-making in oncology. Shortly after, updates from the AACR 2026 conference and a collaboration with GenoPredicta highlighted progress in cancer diagnostics, further emphasizing the company's edge in AI-applied genomics. These developments reinforced TEM's positioning in the burgeoning precision oncology market, where demand for targeted therapies is accelerating.
Additionally, Tempus AI expanded a strategic partnership amid an oncology boom, amplifying its data and applications segment—responsible for robust revenue growth. Positive results from the ALERT trial announcement also contributed, validating the efficacy of its AI tools in real-world clinical settings and driving earlier gains. These operational milestones shifted sentiment positively, countering broader healthcare tech pressures and contributing to a 15% market cap increase to over $10 billion.
On the analyst front, coverage has been active. The consensus remains overweight, with 11 buy ratings among 20 analysts and an average price target of $72.40, implying upside potential. High targets reach $100, reflecting optimism on revenue trajectories. However, Jefferies initiated coverage with an underperform rating and $35 target on April 13, citing valuation concerns post-rally, which introduced short-term caution but did not derail the overall uptrend. Earlier, Q4 2025 earnings beat expectations slightly, with EPS of -$0.04 versus -$0.05 estimated and revenue of $367 million, alongside 2026 guidance for approximately $1.59 billion—signaling 25%+ growth. This reaffirmed execution amid ongoing investments in AI infrastructure.
Macro factors, including AI enthusiasm in healthcare and oncology sector tailwinds, amplified these drivers. While high debt levels (debt-to-equity at 270%) and persistent losses (TTM net income -$245 million) temper enthusiasm, the linkage between news flow and price behavior highlights TEM's sensitivity to innovation milestones.
2026 Outlook and Key Factors to Monitor
Heading into 2026, Tempus AI's trajectory hinges on scaling its AI-driven precision medicine platform, with analyst estimates pegging revenue at around $1.59 billion, driven by diagnostics expansion and data licensing growth. Key opportunities lie in deepening oncology integrations, such as advanced genomic testing and clinical trial matching via partnerships like GenoPredicta, amid rising demand for personalized therapies. The company's multimodal dataset—spanning clinical, molecular, and imaging—positions it to capitalize on AI advancements in drug discovery and patient stratification.
Risks include execution challenges in achieving profitability, given ongoing R&D spend and a high debt-to-equity ratio (total debt/equity 270.11%). Competitive pressures from peers in AI healthcare, regulatory hurdles for new diagnostics (e.g., FDA approvals), and macroeconomic sensitivities in biotech funding warrant vigilance. Investors should track quarterly progress toward guidance, partnership monetization, trial outcomes like ALERT extensions, and cost efficiencies. Balanced against these, TEM's strategic focus on high-growth areas like precision oncology offers a compelling narrative for long-term monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
TEM's RSI Indicator climbs out of oversold territory
The RSI Indicator for TEM moved out of oversold territory on May 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 11 similar instances when the indicator left oversold territory. In of the 11 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 26 cases where TEM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TEM just turned positive on May 28, 2026. Looking at past instances where TEM's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in of 109 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEM as a result. In of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
TEM moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TEM crossed bearishly below the 50-day moving average on June 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TEM broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TEM entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TEM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (21.368) is slightly higher than the industry average of (7.410). P/E Ratio (39.298) is within average values for comparable stocks, (50.038). TEM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.193). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (6.410) is also within normal values, averaging (5.761).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement